Different Doses of Empagliflozin in Patients with Heart Failure with Reduced Ejection Fraction
Source : https://www.jstage.jst.go.jp/article/ihj/advpub/0/advpub_22-151/_article
It was unclear whether there are discrepancies among the efficacy and safety of different doses of empagliflozin in patients with heart failure with reduced ejection fraction (HFrEF). The aim of this study was to compare the efficacy and safety of 25 mg and 10 mg of empagliflozin in HFrEF patients.
Conclusions: The results from this study suggested that 25 mg of empagliflozin might be better than 10 mg in improving heart function in HFrEF patients, and the safety profiles of 25 mg and 10 mg of empagliflozin are comparable. Further studies are expected to substantiate our speculations.